Sugi Predict

Sugi Predict / Compounds / SCHEMBL23966915

SCHEMBL23966915

SCHEMBL23966915

COc1cc(-c2cn(C3CC3)c3ncnc(N)c23)ccc1N

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 9/20 0.67
▸ SRC P12931 8/20 0.66
▸ ABL1 P00519 5/20 0.66
▸ EGFR P00533 5/20 0.66
▸ ABL2 P42684 4/20 0.66
▸ KDR P35968 3/20 0.63
▸ TEK Q02763 2/20 0.63
▸ LCK P06239 1/20 0.63
▸ RET P07949 1/20 0.59
▸ KIF5B P33176 1/20 0.59
▸ KCNH2 Q12809 1/20 0.59
▸ CCDC6 Q16204 1/20 0.59
▸ PIK3CD O00329 1/20 0.59
▸ HCK P08631 1/20 0.59
▸ PIK3CA P42336 1/20 0.59
▸ PIK3CB P42338 1/20 0.59
▸ MTOR P42345 1/20 0.59
▸ PIK3CG P48736 1/20 0.59
▸ EPHB4 P54760 1/20 0.59
▸ PRKDC P78527 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30180912 1.00 RIPK2 (0.67) RIPK2SRCABL1EGFRABL2
SCHEMBL2072160 0.96 SRC (0.73) RIPK2SRCABL1EGFRABL2
SCHEMBL6865257 0.93 SRC (0.63) RIPK2SRCABL1EGFRABL2
SCHEMBL6868849 0.92 SRC (0.59) RIPK2SRCABL1EGFRABL2
SCHEMBL6868528 0.91 TEK (0.70) RIPK2SRCABL1EGFRABL2
SCHEMBL6467070 0.91 TEK (0.70) RIPK2SRCABL1EGFRABL2
SCHEMBL6467066 0.91 TEK (0.70) RIPK2SRCABL1EGFRABL2
SCHEMBL6866525 0.88 SRC (0.56) RIPK2SRCABL1EGFRABL2
SCHEMBL2075167 0.87 SRC (0.73) RIPK2SRCABL1EGFRABL2
SCHEMBL2074179 0.85 SRC (0.59) RIPK2SRCABL1EGFRABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12091413-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2024-09-17 — — US disclosed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 — — EP disclosed
US-20230416259-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2023-12-28 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 — — US disclosed
CN-115843272-A Inhibitors of NEK7 kinase 哈利亚治疗公司 2023-03-24 — — CN disclosed
EP-4146348-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2023-03-15 — — EP disclosed
US-20220064173-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2022-03-03 — — US disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 — — WO disclosed
WO-2021242505-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-02 — — WO disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 — — US disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 — — US disclosed
WO-2021226547-A2 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. (US) 2021-11-11 — — WO disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 — — US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355130-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-12091413-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 RIPK2 23/4885SRC 3388/4885ABL1 4556/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20230416259-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885
US-20220064173-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 RIPK2 56/4885SRC 639/4885ABL1 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.